Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with tumors not expressing PD-L1 may benefit; therefore, testing is not required to select patients for therapy. The Dako PD-L1 IHC 28-8 pharmDx...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Oxford University Press
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035792/ |